Vallon Pharmaceuticals IncNASDAQ:VLONNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3968
- TODAY'S CHANGE (%)-0.0053 (-1.3181%)
- Bid / Lots0.3968/ 24
- Ask / Lots0.4290/ 11
- Open / Previous Close0.3950 / 0.4021
- Day Range
- 52 Week Range
- Volume162,165
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VLON |
|---|---|---|
| 09:32 ET | 6744 | 0.41 |
| 09:34 ET | 5200 | 0.405 |
| 09:36 ET | 100 | 0.405 |
| 09:41 ET | 500 | 0.405 |
| 09:48 ET | 2600 | 0.405 |
| 09:50 ET | 200 | 0.4051 |
| 09:54 ET | 717 | 0.41 |
| 09:56 ET | 2300 | 0.4051 |
| 10:10 ET | 4200 | 0.41 |
| 10:12 ET | 751 | 0.4038 |
| 10:15 ET | 2300 | 0.4005 |
| 10:17 ET | 8128 | 0.4006 |
| 10:24 ET | 500 | 0.3951 |
| 10:26 ET | 100 | 0.3951 |
| 10:28 ET | 4900 | 0.3952 |
| 10:42 ET | 2900 | 0.4 |
| 10:46 ET | 5297 | 0.3951 |
| 10:50 ET | 4160 | 0.3971 |
| 10:53 ET | 1858 | 0.395 |
| 11:04 ET | 21931 | 0.396 |
| 11:06 ET | 4108 | 0.396 |
| 11:08 ET | 17100 | 0.396 |
| 11:09 ET | 2300 | 0.3953 |
| 11:11 ET | 1000 | 0.3902 |
| 11:13 ET | 900 | 0.3932 |
| 11:18 ET | 131 | 0.3905 |
| 11:20 ET | 2279 | 0.397 |
| 11:29 ET | 239 | 0.4005 |
| 11:33 ET | 100 | 0.3967 |
| 12:00 ET | 100 | 0.3968 |
| 12:23 ET | 100 | 0.398649 |
| 12:39 ET | 206 | 0.4 |
| 12:50 ET | 2112 | 0.400251 |
| 12:52 ET | 10000 | 0.3968 |
| 12:56 ET | 669 | 0.3968 |
| 01:26 ET | 800 | 0.3969 |
| 01:33 ET | 910 | 0.3987 |
| 01:39 ET | 3305 | 0.3968 |
| 01:44 ET | 393 | 0.3983 |
| 01:50 ET | 150 | 0.3968 |
| 01:51 ET | 125 | 0.4005 |
| 02:02 ET | 3000 | 0.398651 |
| 02:06 ET | 250 | 0.4005 |
| 02:15 ET | 110 | 0.3986 |
| 02:22 ET | 3962 | 0.4005 |
| 02:33 ET | 1175 | 0.396901 |
| 02:42 ET | 300 | 0.3968 |
| 02:44 ET | 2600 | 0.405 |
| 02:56 ET | 539 | 0.40145 |
| 03:07 ET | 1000 | 0.405 |
| 03:32 ET | 100 | 0.3975 |
| 03:48 ET | 200 | 0.396801 |
| 03:50 ET | 125 | 0.3968 |
| 03:57 ET | 4698 | 0.3968 |
Mar 2, 2023
BRIEF-Vallon Pharmaceuticals Inc - On Feb 28, Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq, from 5:06PM ET on Thursday Mar 02, 2023 by Thomson Reuters
5:06PM ET on Thursday Mar 02, 2023 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vallon Pharmaceuticals Inc | 5.4M | -0.5x | --- |
Avenue Therapeutics Inc | 5.4M | -0.3x | --- |
Qrons Inc | 5.3M | -5.7x | --- |
GlobeStar Therapeutics Corp | 5.2M | -0.8x | --- |
NeuBase Therapeutics Inc | 5.7M | -0.2x | --- |
Capstone Holding Corp | 5.8M | -5.6x | --- |
Company Information
Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel abuse-deterrent medications for central nervous system (CNS) disorders. Its technology is designed to resist manipulation for snorting and provide barriers to injection. The Company’s lead investigational product candidate, Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), an abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. In addition to ADAIR, the Company’s second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin), for the treatment of ADHD.
Contact Information
- Headquarters
- Two Logan Square 100 N. 18Th Street, Suite 300PHILADELPHIA, PA, United States 19103
- Phone
- 267-607-8255
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Director
- David Baker
- Chief Financial Officer
- Leanne Kelly
- Chief Medical Officer
- Timothy Whitake
- Independent Director
- Richard Ammer
- Independent Director
- Meenu Chhabra Karson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 13.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.80 |
Book Value | $0.17 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
